Literature DB >> 12412769

Tetanus surveillance--United States, 1991-1994.

H S Izurieta1, R W Sutter, P M Strebel, B Bardenheier, D R Prevots, M Wharton, S C Hadler.   

Abstract

PROBLEM/CONDITION: Despite the widespread availability of a safe and effective vaccine against tetanus, 201 cases of the disease were reported during 1991-1994. Of patients with known illness outcome, the case-fatality rate was 25%. REPORTING PERIOD COVERED: 1991-1994. DESCRIPTION OF SYSTEM: Physician-diagnosed cases of tetanus are reported to local and state health departments, the latter of which reports these cases on a weekly basis to CDC's National Notifiable Disease Surveillance System. Since 1965, state health departments also have submitted supplemental clinical and epidemiologic information to CDC's National Immunization Program.
RESULTS: During 1991-1994, 201 cases of tetanus were reported from 40 states, for an average annual incidence of 0.02 cases per 100,000 population. Of the 188 patients for whom age was known, 101 (54%) were aged > or = 60 years and 10 (5%) were aged < 20 years. No cases of neonatal tetanus were reported. Among adults, the risk for tetanus increased with age; the risk for persons aged > or = 80 years was more than 10 times greater than the risk for persons aged 20-29 years. All deaths occurred among persons aged > or = 30 years. The case-fatality rate (overall: 25%) increased with age, from 11% in persons aged 30-49 years to 54% in persons aged > or = 80 years. Only 12% of all patients were reported to have received a primary series of tetanus toxoid before onset of illness. For 77% of patients, tetanus occurred after an acute injury was sustained. Of patients who obtained medical care for their injury, only 43% received tetanus toxoid as part of wound prophylaxis.
INTERPRETATION: The epidemiology of reported tetanus in the United States during 1991-1994 was similar to that during the 1980s. Tetanus continued to be a severe disease primarily of older adults who were unvaccinated or inadequately vaccinated. Most tetanus cases occurred after an acute injury was sustained, emphasizing the need for appropriate wound management. ACTIONS TAKEN: In addition to decennial booster doses of tetanus-diphtheria toxoid during adult life, the Advisory Committee on Immunization Practices (ACIP) recommends vaccination visits for adolescents at age 11-12 years and for adults at age 50 years to enable health-care providers to review vaccination histories and administer any needed vaccine. Full implementation of the ACIP recommendations should virtually eliminate the remaining tetanus burden in the United States.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 12412769

Source DB:  PubMed          Journal:  MMWR CDC Surveill Summ


  6 in total

1.  [Insufficient tetanus vaccination protection in psoriasis and systemic immunosuppression : Results of a retrospective investigation of 101 patients].

Authors:  W Sondermann; L Leister; N Rompoti; J Dissemond; J Klode; A Körber
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

2.  Epidemiology of tetanus in the Marches Region of Italy, 1992-95.

Authors:  E Prospero; R Appignanesi; M M D'Errico; F Carle
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 3.  Postsurgical tetanus.

Authors:  Shayesta Dhalla
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

4.  Tetanus immunity in nursing home residents of Bolu, Turkey.

Authors:  Oguz Karabay; Fatma Ozkardes; Ali Tamer; Kazim Karaarslan
Journal:  BMC Public Health       Date:  2005-01-12       Impact factor: 3.295

Review 5.  Healthcare maintenance in elderly patients with inflammatory bowel disease.

Authors:  Manish P Shrestha; Joannie Ruel; Sasha Taleban
Journal:  Ann Gastroenterol       Date:  2017-02-17

6.  Neonatal tetanus in Turkey; what has changed in the last decade?

Authors:  Bunyamin Dikici; Hakan Uzun; Ebru Yilmaz-Keskin; Taskin Tas; Ali Gunes; Halil Kocamaz; Capan Konca; Mehmet A Tas
Journal:  BMC Infect Dis       Date:  2008-08-19       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.